-
公开(公告)号:EP4511022A1
公开(公告)日:2025-02-26
申请号:EP23717999.9
申请日:2023-04-20
Applicant: Université Paris Cité , Centre National de la Recherche Scientifique , Institut National de la Santé et de la Recherche Médicale , Institut Curie , Université Paris-Saclay
IPC: A61K31/4184 , C07D235/18 , A61P29/00 , A61P37/00 , C07D401/04 , C12N5/07
-
公开(公告)号:EP4493672A1
公开(公告)日:2025-01-22
申请号:EP23769398.1
申请日:2023-03-16
Applicant: Ananda Devices Inc.
-
公开(公告)号:EP2464725B2
公开(公告)日:2025-01-15
申请号:EP10745064.5
申请日:2010-08-06
Inventor: GAWLITZEK, Martin , PETRAGLIA, Christina, Teresa , LUO, Shun
-
公开(公告)号:EP4461825A3
公开(公告)日:2024-11-20
申请号:EP24200621.1
申请日:2018-05-04
Applicant: Providence Health & Services - Oregon , Agonox, Inc.
Inventor: WEINBERG, Andrew, D. , MONTLER, Ryan , DUHEN, Thomas , DUHEN, Rebekka
IPC: A61P35/00 , A61K35/17 , C12N5/07 , G01N33/574 , C12Q1/6886
Abstract: Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8+CD39+CD103+ T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD8+CD39+CD103+ T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD8+CD39+CD103+ T cells. In addition, methods are disclosed for expanding CD8+CD39+CD103+ T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD8+CD39+CD103+ T cells in a biological sample from a subject.
-
公开(公告)号:EP4458949A1
公开(公告)日:2024-11-06
申请号:EP24186387.7
申请日:2019-05-22
Applicant: Morphocell Technologies Inc.
Inventor: PAUN, Radu Alexandru , HABIB, Shawana , PAGANELLI, Massimiliano , RAGGI, Claudia
Abstract: A perfusion bioreactor and a perfusion device. Each perfusion device has a mesh structure, and an encapsulated organ tissue (EOT) disposed in the mesh structure. The EOT has a body with a thickness defined between a first surface of the body and a second surface of the body. The body has at least one channel extending into the body from one of the first and second surfaces to receive a fluid therein. The at least one channel has a diameter selected to diffuse solutes out of the fluid and into the body. The perfusion devices are arranged one adjacent to another and spaced apart from each other along the length of the bioreactor to receive fluid, and to perfuse the fluid to the EOT of each perfusion device and to the at least one channel therein. A method of processing blood plasma and an artificial liver system are also disclosed.
-
公开(公告)号:EP4431595A1
公开(公告)日:2024-09-18
申请号:EP22892921.2
申请日:2022-11-14
Applicant: ISM Co., Ltd. , Ochiya, Takahiro , Miyato, Mitsuru
Inventor: OCHIYA, Takahiro , MIYATO, Mitsuru
IPC: C12N5/07
CPC classification number: C12N5/06
Abstract: The present invention relates to a method for long-term culture of colorectal epithelial cells, the method comprising culturing colorectal epithelial cells in the presence of a ROCK inhibitor.
-
-
公开(公告)号:EP4424812A1
公开(公告)日:2024-09-04
申请号:EP22886934.3
申请日:2022-10-24
Applicant: Integriculture Inc.
Inventor: HATANO, Hiroaki , KAWASHIMA, Ikko
Abstract: A cell holding material capable of holding cells, in which a scaffold to which the cells adhere does not become an obstacle to cell observation, and a cell holding method therefor are provided. A certain embodiment of the present invention is a cell holding material, including a frame member for surrounding all or at least part of a planned holding region capable of holding a cell population obtained by aggregating multiple cells, and the cell population in a form of membrane occupying at least part of the planned holding region and being held by the frame member, in which at least part of a margin of the cell population is brought into contact with the frame member, and further a portion occupying the planned holding region in the cell population is in a state of being hung without physical support.
-
9.
公开(公告)号:EP4417621A1
公开(公告)日:2024-08-21
申请号:EP22880203.9
申请日:2022-10-08
Inventor: SUN, Bing , YI, Chunyan , LING, Zhiyang
CPC classification number: A61K39/42 , A61K47/68 , A61P11/06 , A61P31/14 , C07K19/00 , C12N5/06 , C12N5/10 , C12N15/11 , C07K16/1003
Abstract: The present invention provides a design and application of a fully human antibody for neutralizing respiratory syncytial virus. Specifically, in the present invention, germline gene back mutation and affinity enhancement are performed on respiratory syncytial virus fusion protein fully-human monoclonal antibody 4Fl by using computer aided design and site-directed mutagenesis technology. The modified antibody of the present invention has a relatively low number of somatic mutation sites, has high affinity, can effectively prevent RSV infection, and can also effectively inhibit the spread of RSV infection.
-
10.
公开(公告)号:EP4372081A3
公开(公告)日:2024-08-07
申请号:EP24154567.2
申请日:2012-12-31
Applicant: CELLSCRIPT, LLC
Inventor: Meis, Judith , Person, Anthony D. , Chin, Cynthia S. , Jendrisak, Jerome , Dahl, Gary A.
IPC: C12N15/10 , C12N5/07 , C12P19/34 , A61K31/7105 , C12P21/02 , C12N5/074 , C12N5/0793 , A61K33/06 , A61K38/00
CPC classification number: A61K31/7105 , C12P19/34 , C12N5/0696 , C12N15/1003 , C12N15/1096 , C12N5/0619 , C12N2501/6020130101 , C12N2501/60220130101 , C12N2501/60320130101 , C12N2501/60420130101 , C12N2501/60520130101 , C12N2501/60620130101 , C12N2501/60820130101 , C12N2506/130720130101 , C12N2510/0020130101 , A61K33/06 , C12P21/02 , A61K38/005 , C12Y301/26003 , Y02A50/30
Abstract: The present invention relates to compositions, kits and methods for making and using RNA compositions comprising in vitro-synthesized ssRNA inducing a biological or biochemical effect in a mammalian cell or organism into which the RNA composition is repeatedly or continuously introduced. In certain embodiments, the invention provides compositions and methods for changing the state of differentiation or phenotype of a human or other vertebrate cell. For example, the present invention provides mRNA and methods for reprogramming cells that exhibit a first differentiated state or phenotype to cells that exhibit a second differentiated state or phenotype, such as to reprogram human somatic cells to pluripotent stem cells.
-
-
-
-
-
-
-
-
-